News

ConsumerAffairs4h

GoodRx teams up with Novo Nordisk to make weight loss drugs more affordable

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

FDA Approves Wegovy to Treat Serious Liver Disease

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Wegovy News Pushes Novo Nordisk Stock Higher

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

Drugmaker Novo Nordisk freezes hiring for non-critical jobs

Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...

Novo Nordisk Freezes Hiring As Wegovy Faces Copycats

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.
Analytics Insight2d

Novo Nordisk Share Price Rises 5% on Wegovy’s New FDA Approval for MASH

Novo Nordisk share price rose nearly 5% on August 18, 2025. The hike came after the US Food and Drug Administration granted ...
BioSpace2d

Novo Wins MASH Approval for Wegovy

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

Novo Nordisk stock rises, Wegovy approved to treat liver disease

Shares of Novo Nordisk (NVO) are rising early Monday after the US Food and Drug Administration approved Wegovy to treat ...

Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Novo Nordisk A/S: Novo Nordisk to present Wegovy and Ozempic data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European ...

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation - a common heart rhythm condition - in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® da ...